AbelZeta announces publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced hepatocellular carcinoma
ROCKVILLE, Md. and SHANGHAI, July 23, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or "the Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced a...
ROCKVILLE, Md. and SHANGHAI, July 23, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or "the Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced a...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.